On the stock market since 2020, it operates in the world of health and science. It has 2,400 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 33% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 34% a year on average.
Sales run at $414.3M a year. A small number, but proof the product has real buyers.
The average analyst price target is $13.97 — 99% above today’s price.
A loss of $99.8M against $414.3M in annual sales.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 2.4 years. After that, the company needs to find new money.
On our five-subject report card, ACCD sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ACCD is a high-risk stock — not yet profitable, and its future rides on its product catching on.